Jun-Hyeog Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun-Hyeog Jang has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Wonmo Kang
Department of Biochemistry, Inha University School of Medicine, Incheon, 400-712, Republic of Korea
11 shared publications- Hae-Won Kim
Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, Republic of Korea
9 shared publications Hae-Won Kim
Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, South Korea
8 shared publicationsSujin Lee
Department of Biochemistry, Inha University School of Medicine, Incheon 22212, Korea
8 shared publicationsYe-Rang Yun
Industrial Technology Research Group, Research and Development Division, World Institute of Kimchi, Nam, Gwangju 61755, Republic of Korea
8 shared publicationsEunyi Jeon
Department of Biochemistry, Inha University School of Medicine, Incheon, 400-712, Korea
7 shared publications
Latest Publications
- Open Access
Targeting Cellular Senescence and the Extracellular Matrix for Tissue Regeneration: Mechanistic Evidence and a Proposed Therapeutic Framework
Persistent cellular senescence and extracellular matrix (ECM) dysfunction can impair tissue repair, whereas some transient senescence-associated states support healing. This critical narrative review distinguishes evidence for senescent-cell clearance, modulation of senescence-associated phenotypes, and functional tissue repair. A citation-led reassessment supplemented by a targeted literature update was used to examine mechanistic, biomaterial, and clinical evidence; the review was not systematic. Senolytics exhibit cell-type-dependent activity in preclinical models, while ECM-derived materials can support adhesion, survival, and differentiation without demonstrating senolysis. FOXO4–p53-directed peptides, fibronectin modules, and responsive carriers raise unresolved questions regarding target specificity, stereochemistry, intracellular delivery, and potentially antagonistic survival signaling. The studies reviewed do not establish that combining senolysis with ECM-mediated instruction yields superior in vivo regeneration compared with either component treatment alone. We therefore present this integration as a testable hypothesis and propose a two-phase framework, informed by cell-resolved assessment, that preserves acute physiological repair before considering delayed clearance of persistent harmful cell populations. Early human trials provide evidence regarding feasibility, tissue markers, circulating biomarkers, and exploratory functional outcomes, but do not establish regenerative efficacy. Clinical translation requires comparative combination studies, formulation-specific pharmacological and safety assessments, and durable restoration of tissue structure and function.
Open AccessTargeting Cellular Senescence and the Extracellular Matrix for Tissue Regeneration: Mechanistic Evidence and a Proposed Therapeutic Framework
Persistent cellular senescence and extracellular matrix (ECM) dysfunction can impair tissue repair, whereas some transient senescence-associated states support healing. This critical narrative review distinguishes evidence for senescent-cell clearance, modulation of senescence-associated phenotypes, and functional tissue repair. A citation-led reassessment supplemented by a targeted literature update was used to examine mechanistic, biomaterial, and clinical evidence; the review was not systematic. Senolytics exhibit cell-type-dependent activity in preclinical models, while ECM-derived materials can support adhesion, survival, and differentiation without demonstrating senolysis. FOXO4–p53-directed peptides, fibronectin modules, and responsive carriers raise unresolved questions regarding target specificity, stereochemistry, intracellular delivery, and potentially antagonistic survival signaling. The studies reviewed do not establish that combining senolysis with ECM-mediated instruction yields superior in vivo regeneration compared with either component treatment alone. We therefore present this integration as a testable hypothesis and propose a two-phase framework, informed by cell-resolved assessment, that preserves acute physiological repair before considering delayed clearance of persistent harmful cell populations. Early human trials provide evidence regarding feasibility, tissue markers, circulating biomarkers, and exploratory functional outcomes, but do not establish regenerative efficacy. Clinical translation requires comparative combination studies, formulation-specific pharmacological and safety assessments, and durable restoration of tissue structure and function.
- Open Access
- 26 August 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (5) , 519
Extracellular Vesicles at the Interface of Cancer Therapy and Regenerative Medicine: Biology, Bidirectional Roles, and Engineered Therapeutics
Extracellular vesicles (EVs), including exosomes and microvesicles, are nanoscale membrane-enclosed particles that transfer proteins, lipids, mRNAs, and microRNAs between cells. The same communication system is now being developed in two apparently opposing settings: mesenchymal stem/stromal cell (MSC)-derived EVs are explored as cell-free regenerative therapeutics, whereas tumor-derived EVs can promote metastasis, immune evasion, and treatment resistance while also serving as liquid-biopsy biomarkers. Rather than treating these studies separately, this review compares them along shared mechanistic axes: producer-cell identity and state, luminal cargo, membrane and surface composition (including the biomolecular corona), dose and administration route, biodistribution, and recipient-cell context. This cross-field perspective shows that angiogenesis, immunomodulation, matrix remodeling, and tissue tropism are not intrinsically regenerative or oncogenic; their consequences depend on where, how, and to which cells EV signals are delivered. We review EV biology and MISEV2023-aligned nomenclature, examine bidirectional regenerative and cancer-associated functions, and survey engineering strategies for cargo loading and surface modification together with plant-derived exosome-like nanovesicles. We further compare EVs with lipid nanoparticles, adeno-associated viruses, polymers, and virus-like particles, and discuss how engineering can improve potency and targeting while increasing manufacturing and characterization complexity. Finally, we address tumor-related safety considerations for regenerative EVs and the unresolved biological, technical, manufacturing, and regulatory questions that must be addressed for clinical translation.
- 26 August 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (5) , 519
Open AccessExtracellular Vesicles at the Interface of Cancer Therapy and Regenerative Medicine: Biology, Bidirectional Roles, and Engineered Therapeutics
Extracellular vesicles (EVs), including exosomes and microvesicles, are nanoscale membrane-enclosed particles that transfer proteins, lipids, mRNAs, and microRNAs between cells. The same communication system is now being developed in two apparently opposing settings: mesenchymal stem/stromal cell (MSC)-derived EVs are explored as cell-free regenerative therapeutics, whereas tumor-derived EVs can promote metastasis, immune evasion, and treatment resistance while also serving as liquid-biopsy biomarkers. Rather than treating these studies separately, this review compares them along shared mechanistic axes: producer-cell identity and state, luminal cargo, membrane and surface composition (including the biomolecular corona), dose and administration route, biodistribution, and recipient-cell context. This cross-field perspective shows that angiogenesis, immunomodulation, matrix remodeling, and tissue tropism are not intrinsically regenerative or oncogenic; their consequences depend on where, how, and to which cells EV signals are delivered. We review EV biology and MISEV2023-aligned nomenclature, examine bidirectional regenerative and cancer-associated functions, and survey engineering strategies for cargo loading and surface modification together with plant-derived exosome-like nanovesicles. We further compare EVs with lipid nanoparticles, adeno-associated viruses, polymers, and virus-like particles, and discuss how engineering can improve potency and targeting while increasing manufacturing and characterization complexity. Finally, we address tumor-related safety considerations for regenerative EVs and the unresolved biological, technical, manufacturing, and regulatory questions that must be addressed for clinical translation.
- Open Access
- 18 February 2026
- Published by SAGE Publications in Mechanobiology
- Vol. 1
Extracellular matrix mechanics as a master regulator of mechanotransduction in tissue homeostasis and disease
The extracellular matrix (ECM) is a dynamic mechanochemical network that integrates biochemical ligands with physical cues—such as stiffness, viscoelasticity, topography, and confinement—to regulate cell fate and tissue homeostasis. Cells sense and transmit ECM-derived forces through integrin-based adhesions, the actin cytoskeleton, mechanosensitive ion channels, and the LINC complex, coupling cytoplasmic tension to nuclear mechanics, chromatin organization, and transcriptional programs. In this review, we summarize key mechanobiological principles across major ECM contexts and outline how “mechanical niches” are established and remodeled during development and repair. We highlight the adhesion–nucleus–chromatin axis and central transcriptional hubs, including YAP/TAZ-mediated mechanotransduction, that translate extracellular mechanics into gene expression and epigenetic memory. We further discuss how ECM stiffening, altered viscoelastic relaxation, and matrix compositional switching drive disease progression, with emphasis on fibrosis, cancer, and vascular pathologies. Finally, we survey emerging experimental platforms—tunable hydrogels, engineered and decellularized ECM, and quantitative 3D culture/organoid systems—that enable controlled perturbation of ECM mechanics and multiscale readouts. These approaches provide a foundation for improved biomarkers and therapeutic strategies aimed at normalizing pathological microenvironments and restoring tissue function.
- 18 February 2026
- Published by SAGE Publications in Mechanobiology
- Vol. 1
Open AccessExtracellular matrix mechanics as a master regulator of mechanotransduction in tissue homeostasis and disease
The extracellular matrix (ECM) is a dynamic mechanochemical network that integrates biochemical ligands with physical cues—such as stiffness, viscoelasticity, topography, and confinement—to regulate cell fate and tissue homeostasis. Cells sense and transmit ECM-derived forces through integrin-based adhesions, the actin cytoskeleton, mechanosensitive ion channels, and the LINC complex, coupling cytoplasmic tension to nuclear mechanics, chromatin organization, and transcriptional programs. In this review, we summarize key mechanobiological principles across major ECM contexts and outline how “mechanical niches” are established and remodeled during development and repair. We highlight the adhesion–nucleus–chromatin axis and central transcriptional hubs, including YAP/TAZ-mediated mechanotransduction, that translate extracellular mechanics into gene expression and epigenetic memory. We further discuss how ECM stiffening, altered viscoelastic relaxation, and matrix compositional switching drive disease progression, with emphasis on fibrosis, cancer, and vascular pathologies. Finally, we survey emerging experimental platforms—tunable hydrogels, engineered and decellularized ECM, and quantitative 3D culture/organoid systems—that enable controlled perturbation of ECM mechanics and multiscale readouts. These approaches provide a foundation for improved biomarkers and therapeutic strategies aimed at normalizing pathological microenvironments and restoring tissue function.
- Top Cited PapersOpen Access
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 247
Extracellular Matrix in Human Disease and Therapy: From Pathogenic Remodeling to Biomaterial Platforms and Precision Diagnostics
The extracellular matrix (ECM) is a dynamic, tissue-specific network that integrates biochemical and mechanical cues to regulate cell behavior and organ homeostasis. Increasing evidence indicates that dysregulated ECM remodeling is an upstream driver of chronic human diseases rather than a passive consequence of injury. This review summarizes principles of ECM organization, mechanotransduction, and pathological remodeling and highlights translational opportunities for ECM-targeted therapies, biomaterial platforms, and precision diagnostics. We conducted a narrative synthesis of foundational and recent literature covering ECM composition and turnover, stiffness-dependent signaling, and disease-associated remodeling across fibrosis/cardiovascular disease, cancer, and metabolic disorders, together with advances in ECM-based biomaterials, drug delivery, and ECMderived biomarkers and imaging. Across organs, a self-reinforcing cycle of altered matrix composition, excessive crosslinking, and stiffness-dependent mechanotransduction (including integrin–FAK and YAP/TAZ pathways) sustains fibroinflammation, myofibroblast persistence, and progressive tissue dysfunction. In tumors, aligned and crosslinked ECM promotes invasion, immune evasion, and therapy resistance while also shaping perfusion and drug penetration. Translational strategies increasingly focus on modulating ECM synthesis and crosslinking, normalizing rather than ablating matrix architecture, and targeting ECM–cell signaling axes in combination with anti-fibrotic, cytotoxic, or immunotherapeutic regimens. ECM biology provides a unifying framework linking pathogenesis, therapy, and precision diagnostics across chronic diseases. Clinical translation will benefit from standardized quantitative measures of matrix remodeling, mechanism-based biomarkers of ECM turnover, and integrative imaging–omics approaches for patient stratification and treatment monitoring.
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 247
Top Cited PapersOpen AccessExtracellular Matrix in Human Disease and Therapy: From Pathogenic Remodeling to Biomaterial Platforms and Precision Diagnostics
The extracellular matrix (ECM) is a dynamic, tissue-specific network that integrates biochemical and mechanical cues to regulate cell behavior and organ homeostasis. Increasing evidence indicates that dysregulated ECM remodeling is an upstream driver of chronic human diseases rather than a passive consequence of injury. This review summarizes principles of ECM organization, mechanotransduction, and pathological remodeling and highlights translational opportunities for ECM-targeted therapies, biomaterial platforms, and precision diagnostics. We conducted a narrative synthesis of foundational and recent literature covering ECM composition and turnover, stiffness-dependent signaling, and disease-associated remodeling across fibrosis/cardiovascular disease, cancer, and metabolic disorders, together with advances in ECM-based biomaterials, drug delivery, and ECMderived biomarkers and imaging. Across organs, a self-reinforcing cycle of altered matrix composition, excessive crosslinking, and stiffness-dependent mechanotransduction (including integrin–FAK and YAP/TAZ pathways) sustains fibroinflammation, myofibroblast persistence, and progressive tissue dysfunction. In tumors, aligned and crosslinked ECM promotes invasion, immune evasion, and therapy resistance while also shaping perfusion and drug penetration. Translational strategies increasingly focus on modulating ECM synthesis and crosslinking, normalizing rather than ablating matrix architecture, and targeting ECM–cell signaling axes in combination with anti-fibrotic, cytotoxic, or immunotherapeutic regimens. ECM biology provides a unifying framework linking pathogenesis, therapy, and precision diagnostics across chronic diseases. Clinical translation will benefit from standardized quantitative measures of matrix remodeling, mechanism-based biomarkers of ECM turnover, and integrative imaging–omics approaches for patient stratification and treatment monitoring.
- Open Access
- 21 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9218
FN9-10ELP, an ECM-Mimetic Fusion Protein, Protects Human Mesenchymal Stem Cells from Etoposide-Induced Senescence
Cellular senescence is a major barrier to the therapeutic application of human mesenchymal stem cells (hMSCs), as it compromises their proliferative capacity, differentiation potential, and regenerative efficacy. In this study, we investigated whether FN9-10ELP, a recombinant extracellular matrix (ECM)-mimetic fusion protein composed of fibronectin type III domains 9 and 10 conjugated to elastin-like polypeptides (ELPs), could attenuate etoposide-induced senescence in human turbinate-derived MSCs (hTMSCs). Premature senescence was induced by treatment with 20 µM etoposide, and the protective effects of FN9-10ELP were evaluated in terms of cell viability (using the MTT assay), senescence-associated gene expression (by RT-qPCR analysis), nuclear morphology (after staining with 4’,6-diamidino-2-phenylindole (DAPI)), and SA-β-galactosidase activity. FN9-10ELP treatment significantly improved cell viability and reduced the expression of senescence-associated secretory phenotype (SASP) genes, including interleukin-6 (IL-6), interleukin-8 (IL-8), and plasminogen activator inhibitor-1 (PAI-1). Furthermore, FN9-10ELP alleviated nuclear enlargement and decreased the proportion of SA-β-gal-positive cells, indicating suppression of the senescence phenotype. These findings demonstrate that FN9-10ELP effectively counteracts chemotherapy-induced senescence in hMSCs and highlight its potential as a promising biomaterial for regenerative medicine and anti-aging therapies.
- 21 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9218
Open AccessFN9-10ELP, an ECM-Mimetic Fusion Protein, Protects Human Mesenchymal Stem Cells from Etoposide-Induced Senescence
Cellular senescence is a major barrier to the therapeutic application of human mesenchymal stem cells (hMSCs), as it compromises their proliferative capacity, differentiation potential, and regenerative efficacy. In this study, we investigated whether FN9-10ELP, a recombinant extracellular matrix (ECM)-mimetic fusion protein composed of fibronectin type III domains 9 and 10 conjugated to elastin-like polypeptides (ELPs), could attenuate etoposide-induced senescence in human turbinate-derived MSCs (hTMSCs). Premature senescence was induced by treatment with 20 µM etoposide, and the protective effects of FN9-10ELP were evaluated in terms of cell viability (using the MTT assay), senescence-associated gene expression (by RT-qPCR analysis), nuclear morphology (after staining with 4’,6-diamidino-2-phenylindole (DAPI)), and SA-β-galactosidase activity. FN9-10ELP treatment significantly improved cell viability and reduced the expression of senescence-associated secretory phenotype (SASP) genes, including interleukin-6 (IL-6), interleukin-8 (IL-8), and plasminogen activator inhibitor-1 (PAI-1). Furthermore, FN9-10ELP alleviated nuclear enlargement and decreased the proportion of SA-β-gal-positive cells, indicating suppression of the senescence phenotype. These findings demonstrate that FN9-10ELP effectively counteracts chemotherapy-induced senescence in hMSCs and highlight its potential as a promising biomaterial for regenerative medicine and anti-aging therapies.
- Open Access
- 31 July 2025
- Published by MDPI AG in Preprints.org
FN9-10ELP, an ECM-Mimetic Fusion Protein, Suppresses Etoposide-Induced Senescence in Human Mesenchymal Stem Cells
Background: Cellular senescence impairs the therapeutic potential of mesenchymal stem cells (MSCs), limiting their clinical applications. In this study, we aimed to eval-uate whether FN9-10ELP, a recombinant ECM-mimetic fusion protein composed of fi-bronectin type III domains 9 and 10 conjugated to elastin-like polypeptides, could sup-press senescence induced by the chemotherapeutic agent etoposide in hTMSCs. Methods: Senescence was induced in hTMSCs by treatment with 20μM etoposide. The anti-senescence effects of FN9-10ELP were evaluated by assessing cell viability (MTT assay), senescence-associated gene expression (qRT-PCR), nuclear morphology (DAPI staining), and SA-β-galactosidase activity. Results: FN9-10ELP treatment significantly enhanced cell viability and attenuated the mRNA expression of senescence-associated secretory phenotype (SASP) genes, in-cluding IL-6, IL8, and PAI-1. Furthermore, FN9-10ELP reduced etoposide-induced nu-clear enlargement and decreased the proportion of SA-β-gal-positive cells, indicating attenuation of the senescence phenotype. Conclusions: FN9-10ELP suppresses etoposide-induced senescence in hTMSCs by pre-serving cell viability and reducing the expression of SASP factors and morphological senescence markers. These findings highlight the potential of ECM-mimetic proteins such as FN9-10ELP as promising biomaterials in regenerative medicine and anti-aging therapies.
- 31 July 2025
- Published by MDPI AG in Preprints.org
Open AccessFN9-10ELP, an ECM-Mimetic Fusion Protein, Suppresses Etoposide-Induced Senescence in Human Mesenchymal Stem Cells
Background: Cellular senescence impairs the therapeutic potential of mesenchymal stem cells (MSCs), limiting their clinical applications. In this study, we aimed to eval-uate whether FN9-10ELP, a recombinant ECM-mimetic fusion protein composed of fi-bronectin type III domains 9 and 10 conjugated to elastin-like polypeptides, could sup-press senescence induced by the chemotherapeutic agent etoposide in hTMSCs. Methods: Senescence was induced in hTMSCs by treatment with 20μM etoposide. The anti-senescence effects of FN9-10ELP were evaluated by assessing cell viability (MTT assay), senescence-associated gene expression (qRT-PCR), nuclear morphology (DAPI staining), and SA-β-galactosidase activity. Results: FN9-10ELP treatment significantly enhanced cell viability and attenuated the mRNA expression of senescence-associated secretory phenotype (SASP) genes, in-cluding IL-6, IL8, and PAI-1. Furthermore, FN9-10ELP reduced etoposide-induced nu-clear enlargement and decreased the proportion of SA-β-gal-positive cells, indicating attenuation of the senescence phenotype. Conclusions: FN9-10ELP suppresses etoposide-induced senescence in hTMSCs by pre-serving cell viability and reducing the expression of SASP factors and morphological senescence markers. These findings highlight the potential of ECM-mimetic proteins such as FN9-10ELP as promising biomaterials in regenerative medicine and anti-aging therapies.
- Open Access
- 7 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3092
Regeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant liver ailment attributed to factors like obesity and diabetes. While ongoing research explores treatments for NAFLD, further investigation is imperative to address this escalating health concern. NAFLD manifests as hepatic steatosis, precipitating insulin resistance and metabolic syndrome. This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21) and Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells. AML12, a murine hepatocyte cell line, was utilized to gauge the regenerative effects of chimeric FGF21/HGFR expression. Polysaccharide accumulation was affirmed through Periodic acid–Schiff (PAS) staining, while LDL uptake was microscopically observed with labeled LDL. The expression of FGF21/HGFR and NAFLD markers was analyzed by mRNA analysis with RT-PCR, which showed a decreased expression in acetyl-CoA carboxylase 1 (ACC1) and sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) with increased expression of hepatocellular growth factor (HGF), hepatocellular nuclear factor 4 alpha (HNF4A), and albumin (ALB). These findings affirm the hepato-regenerative properties of chimeric FGF21/HGFR within AML12 cells, opening novel avenues for therapeutic exploration in NAFLD.
- 7 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3092
Open AccessRegeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant liver ailment attributed to factors like obesity and diabetes. While ongoing research explores treatments for NAFLD, further investigation is imperative to address this escalating health concern. NAFLD manifests as hepatic steatosis, precipitating insulin resistance and metabolic syndrome. This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21) and Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells. AML12, a murine hepatocyte cell line, was utilized to gauge the regenerative effects of chimeric FGF21/HGFR expression. Polysaccharide accumulation was affirmed through Periodic acid–Schiff (PAS) staining, while LDL uptake was microscopically observed with labeled LDL. The expression of FGF21/HGFR and NAFLD markers was analyzed by mRNA analysis with RT-PCR, which showed a decreased expression in acetyl-CoA carboxylase 1 (ACC1) and sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) with increased expression of hepatocellular growth factor (HGF), hepatocellular nuclear factor 4 alpha (HNF4A), and albumin (ALB). These findings affirm the hepato-regenerative properties of chimeric FGF21/HGFR within AML12 cells, opening novel avenues for therapeutic exploration in NAFLD.
- Open Access
- 15 December 2023
- Published by MDPI AG in Preprints.org
Regeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant liver ailment attributed to factors like obesity and diabetes. While ongoing research explores treatments for NAFLD, further investigation is imperative to address this escalating health concern. NAFLD manifests as hepatic steatosis, precipitating insulin resistance and metabolic syndrome. This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21)-Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells. AML12, a murine hepatocyte cell line, was utilized to gauge the regenerative effects of chimeric FGF21/HGFR expression. Polysaccharide accumulation was affirmed through periodic acid-Schiff (PAS) staining, while LDL uptake was microscopically observed with labeled LDL. mRNA analysis via RT-PCR revealed reduced expression of key NAFLD markers, including acetyl-CoA carboxylase 1 (ACC1) and sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), alongside elevated levels of hepatocyte growth factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), and albumin (ALB). These findings affirm the hepatoregenerative properties of chimeric FGF21/HGFR within AML12 cells, opening novel avenues for NAFLD therapeutic exploration.
- 15 December 2023
- Published by MDPI AG in Preprints.org
Open AccessRegeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant liver ailment attributed to factors like obesity and diabetes. While ongoing research explores treatments for NAFLD, further investigation is imperative to address this escalating health concern. NAFLD manifests as hepatic steatosis, precipitating insulin resistance and metabolic syndrome. This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21)-Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells. AML12, a murine hepatocyte cell line, was utilized to gauge the regenerative effects of chimeric FGF21/HGFR expression. Polysaccharide accumulation was affirmed through periodic acid-Schiff (PAS) staining, while LDL uptake was microscopically observed with labeled LDL. mRNA analysis via RT-PCR revealed reduced expression of key NAFLD markers, including acetyl-CoA carboxylase 1 (ACC1) and sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), alongside elevated levels of hepatocyte growth factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), and albumin (ALB). These findings affirm the hepatoregenerative properties of chimeric FGF21/HGFR within AML12 cells, opening novel avenues for NAFLD therapeutic exploration.
- 1 February 2022
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 29 (2) , 176-183
Construction and Evaluation of Recombinant Chimeric Fibrillin and Elastin Fragment in Human Mesenchymal Stem Cells
Background: Diverse extracellular matrix (ECM) proteins physically interact with stem cells and regulate stem cell function. However, the large molecular weight of the natural ECM renders large-scale fabrication of a similar functional structure challenging. Objective: The objective of this study was to construct a low molecular weight and multifunctional chimeric form of recombinant ECM to stimulate mesenchymal stem cell (MSC) for tissue repair. We engineered Fibrillin-1PF14 fused to an elastin-like polypeptide to develop a new biomimetic ECM for stem cell differentiation and investigated whether this recombinant chimeric Fibrillin-Elastin fragment (rcFE) was effective on human nasal inferior turbinate-derived mesenchymal stem cells (hTMSCs). Methods: hTMSCs were grown in the medium supplemented with rcFE, then the effect of the protein was confirmed through cell adhesion assay, proliferation assay, and real-time PCR. Results: rcFE enhanced the adhesion activity of hTMSCs by 2.7-fold at the optimal concentration, and the proliferation activity was 2.6-fold higher than that of the control group (non-treatment rcFE). In addition, when smooth muscle cell differentiation markers were identified by real-time PCR, Calponin increased about 6-fold, α-actin about 9-fold, and MYH11 about 10-fold compared to the control group. Conclusion: Chimeric rcFE enhanced cellular functions such as cell adhesion, proliferation, and smooth muscle differentiation of hTMSCs, suggesting that the rcFE can facilitate the induction of tissue regeneration.
- 1 February 2022
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 29 (2) , 176-183
Construction and Evaluation of Recombinant Chimeric Fibrillin and Elastin Fragment in Human Mesenchymal Stem Cells
Background: Diverse extracellular matrix (ECM) proteins physically interact with stem cells and regulate stem cell function. However, the large molecular weight of the natural ECM renders large-scale fabrication of a similar functional structure challenging. Objective: The objective of this study was to construct a low molecular weight and multifunctional chimeric form of recombinant ECM to stimulate mesenchymal stem cell (MSC) for tissue repair. We engineered Fibrillin-1PF14 fused to an elastin-like polypeptide to develop a new biomimetic ECM for stem cell differentiation and investigated whether this recombinant chimeric Fibrillin-Elastin fragment (rcFE) was effective on human nasal inferior turbinate-derived mesenchymal stem cells (hTMSCs). Methods: hTMSCs were grown in the medium supplemented with rcFE, then the effect of the protein was confirmed through cell adhesion assay, proliferation assay, and real-time PCR. Results: rcFE enhanced the adhesion activity of hTMSCs by 2.7-fold at the optimal concentration, and the proliferation activity was 2.6-fold higher than that of the control group (non-treatment rcFE). In addition, when smooth muscle cell differentiation markers were identified by real-time PCR, Calponin increased about 6-fold, α-actin about 9-fold, and MYH11 about 10-fold compared to the control group. Conclusion: Chimeric rcFE enhanced cellular functions such as cell adhesion, proliferation, and smooth muscle differentiation of hTMSCs, suggesting that the rcFE can facilitate the induction of tissue regeneration.
- Open Access
- 16 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260760
Bio-functionalization and in-vitro evaluation of titanium surface with recombinant fibronectin and elastin fragment in human mesenchymal stem cell
Titanium is a biomaterial that meets a number of important requirements, including excellent mechanical and chemical properties, but has low bioactivity. To improve cellular response onto titanium surfaces and hence its osseointegration, the titanium surface was bio-functionalized to mimic an extracellular matrix (ECM)-like microenvironment that positively influences the behavior of stem cells. In this respect, fibronectin and elastin are important components of the ECM that regulate stem cell differentiation by supporting the biological microenvironment. However, each native ECM is unsuitable due to its high production cost and immunogenicity. To overcome these problems, a recombinant chimeric fibronectin type III9-10 and elastin-like peptide fragments (FN9-10ELP) was developed herein and applied to the bio-functionalized of the titanium surface. An evaluation of the biological activity and cellular responses with respect to bone regeneration indicated a 4-week sustainability on the FN9-10ELP functionalized titanium surface without an initial burst effect. In particular, the adhesion and proliferation of human mesenchymal stem cells (hMSCs) was significantly increased on the FN9-10ELP coated titanium compared to that observed on the non-coated titanium. The FN9-10ELP coated titanium induced osteogenic differentiation such as the alkaline phosphatase (ALP) activity and mineralization activity. In addition, expressions of osteogenesis-related genes such as a collagen type I (Col I), Runt-related transcription factor 2 (RUNX2), osteopontin (OPN), osteocalcin (OCN), bone sialo protein (BSP), and PDZ-binding motif (TAZ) were further increased. Thus, in vitro the FN9-10ELP functionalization titanium not only sustained bioactivity but also induced osteogenic differentiation of hMSCs to improve bone regeneration.
- 16 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260760
Open AccessBio-functionalization and in-vitro evaluation of titanium surface with recombinant fibronectin and elastin fragment in human mesenchymal stem cell
Titanium is a biomaterial that meets a number of important requirements, including excellent mechanical and chemical properties, but has low bioactivity. To improve cellular response onto titanium surfaces and hence its osseointegration, the titanium surface was bio-functionalized to mimic an extracellular matrix (ECM)-like microenvironment that positively influences the behavior of stem cells. In this respect, fibronectin and elastin are important components of the ECM that regulate stem cell differentiation by supporting the biological microenvironment. However, each native ECM is unsuitable due to its high production cost and immunogenicity. To overcome these problems, a recombinant chimeric fibronectin type III9-10 and elastin-like peptide fragments (FN9-10ELP) was developed herein and applied to the bio-functionalized of the titanium surface. An evaluation of the biological activity and cellular responses with respect to bone regeneration indicated a 4-week sustainability on the FN9-10ELP functionalized titanium surface without an initial burst effect. In particular, the adhesion and proliferation of human mesenchymal stem cells (hMSCs) was significantly increased on the FN9-10ELP coated titanium compared to that observed on the non-coated titanium. The FN9-10ELP coated titanium induced osteogenic differentiation such as the alkaline phosphatase (ALP) activity and mineralization activity. In addition, expressions of osteogenesis-related genes such as a collagen type I (Col I), Runt-related transcription factor 2 (RUNX2), osteopontin (OPN), osteocalcin (OCN), bone sialo protein (BSP), and PDZ-binding motif (TAZ) were further increased. Thus, in vitro the FN9-10ELP functionalization titanium not only sustained bioactivity but also induced osteogenic differentiation of hMSCs to improve bone regeneration.